Aptose Biosciences Inc. (TSX:APS)
2.370
+0.030 (1.28%)
Apr 17, 2026, 12:49 PM EST
Aptose Biosciences Employees
Aptose Biosciences had 14 employees as of December 31, 2025. The number of employees increased by 1 or 7.69% compared to the previous year.
Employees
14
Change (1Y)
1
Growth (1Y)
7.69%
Revenue / Employee
n/a
Profits / Employee
-2.49M CAD
Market Cap
6.05M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 14 | 1 | 7.69% | 14 | 0 |
| Dec 31, 2024 | 13 | -23 | -63.89% | 13 | 0 |
| Dec 31, 2023 | 36 | 0 | - | 35 | 1 |
| Dec 31, 2022 | 36 | -6 | -14.29% | 35 | 1 |
| Dec 31, 2021 | 42 | 1 | 2.44% | 41 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Aptose Biosciences News
- 18 days ago - Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights - GlobeNewsWire
- 27 days ago - Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan of Arrangement - GlobeNewsWire
- 4 weeks ago - Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote “FOR” Proposed Plan of Arrangement with Hanmi Pharmaceutical - GlobeNewsWire
- 4 months ago - Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC - GlobeNewsWire
- 4 months ago - Aptose's Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations - GlobeNewsWire
- 5 months ago - Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical - GlobeNewsWire
- 5 months ago - Aptose Reports Third Quarter 2025 Results - GlobeNewsWire
- 6 months ago - Aptose's Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML - GlobeNewsWire